Compare Ascendis Pharma A/S (ASND) vs Indonesia Energy Corporation Limited (INDO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Indonesia Energy Corporation Limited — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Indonesia Energy Corporation Limited trades at $2.76 (market cap $42.16M). The key difference: Ascendis Pharma A/S is far larger — about 420.8× Indonesia Energy Corporation Limited's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Indonesia Energy Corporation Limited nearer its low. Which is the better fit depends on your goals.
| ASND | INDO | |
|---|---|---|
Market Cap | $17.74B | $42.16M |
Sector | Health | Energy |
52-Week High | $277.18 | $6.74 |
52-Week Low | $163.32 | $2.49 |
Enterprise Value | $18.11B | $37.53M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
INDO trades at $2.74, down 0.72% today, with a neutral technical signal. The company shows negative profitability with a net income margin of -253.4% and a P/S ratio of 19.96, indicating high valuation relative to sales. Recent news highlights operational progress, including the commencement of drilling at the Kruh Block, which could drive future revenue growth. Analyst consensus is unanimously bullish with 3 buy ratings.
The outlook hinges on successful execution of new well operations to improve financials. Risks include persistent losses and oil market volatility. Upside potential exists if production targets are met, but investors should weigh high operational risks against speculative growth prospects in the near term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Indonesia Energy Corporation Limited
Indonesia Energy is an oil and gas exploration and production company. It focuses on identifying and developing energy resources in Indonesia, primarily through its Kruh and Citarum blocks.
Read more on INDO →
